BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair

被引:204
|
作者
O'Donovan, Peter J. [1 ]
Livingston, David M. [1 ]
机构
[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
关键词
DEPENDENT PROTEIN-KINASE; HOMOLOGY-DIRECTED REPAIR; END-JOINING PATHWAYS; HOLLIDAY JUNCTION RESOLVASE; LIGASE-IV; BRCA1/BARD1; HETERODIMER; EXPRESSION PROFILES; FACILITATES REPAIR; COMPLEX-FORMATION; TARGETS BRCA1;
D O I
10.1093/carcin/bgq069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRCA1 and BRCA2 are tumor suppressor genes, familial mutations in which account for similar to 5% of breast cancer cases in the USA annually. Germ line mutations in BRCA1 that truncate or inactivate the protein lead to a cumulative risk of breast cancer, by age 70, of up to 80%, whereas the risk of ovarian cancer is 30-40%. For germ line BRCA2 mutations, the breast cancer cumulative risk approaches 50%, whereas for ovarian cancers, it is between 10 and 15%. Both BRCA1 and BRCA2 are involved in maintaining genome integrity at least in part by engaging in DNA repair, cell cycle checkpoint control and even the regulation of key mitotic or cell division steps. Unsurprisingly, the complete loss of function of either protein leads to a dramatic increase in genomic instability. How they function in maintaining genome integrity after the onset of DNA damage will be the focus of this review.
引用
收藏
页码:961 / 967
页数:7
相关论文
共 50 条
  • [31] Germline mutations in cancer susceptibility genes in BRCA1 and BRCA2 negative families with ovarian and breast cancer
    Norquist, B.
    Harrell, M.
    Walsh, T.
    Mandell, J.
    Bernards, S.
    Agnew, K.
    Lee, M.
    Pennington, K.
    King, M. C.
    Swisher, E.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [32] Clinical implications of the breast cancer susceptibility genes BRCA1 and BRCA2
    Narod, Steven A.
    WOMENS HEALTH, 2005, 1 (01) : 27 - 34
  • [33] Germline mutations in cancer susceptibility genes in brca1 and brca2 negative families with ovarian and breast cancer
    Norquist, B.
    Harrell, M.
    Walsh, T.
    Mandell, J.
    Agnew, K.
    Lee, M.
    Pennington, K.
    King, M. C.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 383 - 383
  • [34] Hereditary breast/ovarian cancer families: beyond BRCA1 and BRCA2
    Fragoso, S.
    Santos, S.
    Mira, B.
    Machado, P.
    Luis, A.
    Clara, A.
    Opiniao, A.
    Bento, S.
    Miguel, I.
    Rodrigues, P.
    Parreira, J.
    Simoes, C.
    Vaz, F.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 568 - 568
  • [35] Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Liede, A
    Malik, IA
    Aziz, Z
    de los Rios, P
    Kwan, E
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) : 595 - 606
  • [36] Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2
    Berchuck, A
    Carney, M
    Lancaster, JM
    Marks, J
    Futreal, AP
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1998, 41 (01): : 157 - 166
  • [37] Missense Polymorphisms in BRCA1 and BRCA2 and Risk of Breast and Ovarian Cancer
    Dombernowsky, Sarah Louise
    Weischer, Maren
    Freiberg, Jacob Johannes
    Bojesen, Stig Egil
    Tybjaerg-Hansen, Anne
    Nordestgaard, Borge Gronne
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (08) : 2339 - 2342
  • [38] Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
    Petrucelli, Nancie
    Daly, Mary B.
    Feldman, Gerald L.
    GENETICS IN MEDICINE, 2010, 12 (05) : 245 - 259
  • [39] The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Metcalfe, KA
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olivotto, IA
    Foulkes, WD
    Warner, E
    Olopade, O
    Eisen, A
    Weber, B
    McLennan, J
    Sun, P
    Narod, SA
    GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 222 - 226
  • [40] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453